Arabic Arabic English English French French German German
dark

New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology Hybrid Congress

Takeda Pharmaceutical Company Limited announced results from two final analyses from the Phase 3 HELP Study™ Open-label Extension, which evaluated the long-term safety and efficacy of TAKHZYRO® 300 mg every two weeks for up to 2.5 years. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by 80 Percent from Baseline

Next Post

Fenbendazole dosage

Related Posts
Total
0
Share